FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you.
XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program
Relevant for: People with triple negative breast cancer, In portal: Breast Cancer
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
View Related Clinical TrialsStudy : Promising research using a PARP inhibitor to treat metastatic breast cancer in people with an inherited PALB2 mutation or a tumor mutation in BRCA1 or BRCA2
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
View Related Clinical TrialsMost relevant for: People with metastatic breast cancer with an inherited mutation in PALB2 or tumor with a BRCA mutation
Early results of a small study showed that women with metastatic breast cancer and an inherited mutation in PALB2 or an acquired tumor mutation in BRCA1 or BRCA2 benefitted from the PARP inhibitor olaparib (Lynparza). (6/18/20)
Read MoreUpdate : FDA approves new treatment for metastatic triple-negative breast cancer
Most relevant for: People with metastatic triple-negative breast cancer who have received at least two prior lines of treatment
The FDA approved the use of sacituzumab govitecan-hizy (Trodelvy), a treatment drug for people with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease. (4/27/20)
Read MorePersonal Story : Improving the quality of life for people with metastatic breast cancer
Most relevant for: People diagnosed with metastatic breast cancer
A Washington Post article described the cancer experience of a young woman living with metastatic breast cancer. It also highlights how integrative medicine and palliative care, including acupuncture, massage, yoga, pain management, mental health therapy and nutrition can improve quality of life for people with metastatic cancer. (3/10/20)
Este artículo está disponible en español.
Read MoreStudy : Can taking dietary supplements during chemotherapy do more harm than good?
Most relevant for: People undergoing breast cancer treatment with chemotherapy
It's common for people to take dietary supplements after being diagnosed with cancer; however, they may reduce how well chemotherapy works. A new study suggests that some dietary supplements may cause more harm than benefit for breast cancer patients who are undergoing chemotherapy. (3/4/20)
Read MoreStudy : Racial and ethnic differences in genetic testing among young breast cancer survivors
Most relevant for: Women diagnosed with breast cancer at age 50 or younger
Genetic testing is recommended for most women who are diagnosed with breast cancer at age 50 or younger. In this study of young women with breast cancer, while the rates of genetic testing did not differ, the rates of women testing positive for an inherited mutation associated with breast cancer did vary between racial and ethnic groups. (2/27/20)
Este artículo está disponible en español.
Read MoreStudy : How does a breast cancer diagnosis affect employment of young women?
Most relevant for: Young women with breast cancer
Most young women who are diagnosed with breast cancer remain employed one year after their diagnosis. Among breast cancer patients who were unemployed a year later, half reported that their unemployment was due to health issues. The issues that were most associated with unemployment were stage of cancer and financial stress prior to diagnosis. (1/10/20)
Read MoreRelevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
Study : Research on the PARP inhibitor talazoparib (Talzenna) for early-stage breast cancer is promising
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
Most relevant for: People with early stage breast cancer who have an inherited BRCA mutation
The PARP inhibitor talazoparib (Talzenna) has been useful for treatment of advanced or metastatic breast cancer for patients with BRCA mutations. A preliminary study showed that the majority of patients who took talazoparib alone before surgery for early-stage breast cancer had effective treatment and manageable side effects. Expanded clinical trials are in progress to verify this result. (10/4/19)
Read MoreRelevance: Medium-High
Strength of Science: Medium
Research Timeline: Post Approval
View Related Clinical TrialsStudy : Inherited mutations in metastatic breast cancer patients
Relevance: Medium-High
Strength of Science: Medium
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: People with metastatic breast cancer
Recent research shows that a significant portion of patients with metastatic breast cancer have harmful mutations in a gene associated with hereditary breast cancer and increased breast cancer risk. (9/26/19)
Read MoreRelevance: High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsStudy : Is it safe for BRCA mutation carriers to become pregnant following breast cancer?
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: Women with a BRCA mutation who are considering pregnancy after breast cancer
New research shows that pregnancy after breast cancer is safe for women with BRCA mutations and their babies. (9/4/19)
Read MoreStudy : Supportive care can improve quality of life for people with metastatic breast cancer
Most relevant for: People diagnosed with metastatic breast cancer
Metastatic breast cancer patients have unique needs for treatment and care. Connecting patients to appropriate support services and palliative care is an area of need in health care. A recent study reported improvement in metastatic breast cancer patient quality of life and wellness with an intervention program called the Supportive, Education and Advocacy (MBC-SEA) program. (8/21/19)
Read More